Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Our understanding of the clinical implications of eosinophilic airway inflammation has increased significantly over the last 20 years, aided by the development of noninvasive means to assess it. This pattern of airway inflammation can occur in a diverse range of airway diseases. It is associated with a positive response to corticosteroids and a high risk of preventable exacerbations. Our new understanding of the role of eosinophilic airway inflammation has paved the way for the clinical development of a number of more specific inhibitors that may become new treatment options. Different definitions, ideas of disease, and adoption of biomarkers that are not well known are necessary to fully realize the potential of these treatments.

Original publication

DOI

10.1513/AnnalsATS.201306-168AW

Type

Journal article

Journal

Ann Am Thorac Soc

Publication Date

12/2013

Volume

10 Suppl

Pages

S143 - S149

Keywords

Adrenal Cortex Hormones, Asthma, Bronchial Hyperreactivity, Bronchitis, Eosinophilia, Eosinophils, Humans, Inflammation, Lung, Phenotype, Sputum, Treatment Outcome